State Street’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$170M Sell
6,863,060
-44,562
-0.6% -$1.06M 0.01% 1035
2025
Q4
$161M Buy
6,907,622
+502,235
+8% +$11.2M 0.01% 1076
2025
Q3
$126M Buy
6,405,387
+926,999
+17% +$19.1M ﹤0.01% 1208
2025
Q2
$119M Sell
5,478,388
-52,049
-0.9% -$1.23M ﹤0.01% 1211
2025
Q1
$134M Sell
5,530,437
-266,123
-5% -$5.99M 0.01% 1114
2024
Q4
$121M Buy
5,796,560
+111,230
+2% +$2.39M ﹤0.01% 1232
2024
Q3
$113M Sell
5,685,330
-347,968
-6% -$6.45M ﹤0.01% 1261
2024
Q2
$93.5M Sell
6,033,298
-2,119,604
-26% -$33M ﹤0.01% 1306
2024
Q1
$130M Buy
8,152,902
+1,365,570
+20% +$20.6M 0.01% 1147
2023
Q4
$114M Sell
6,787,332
-783,363
-10% -$10.7M 0.01% 1215
2023
Q3
$88.5M Sell
7,570,695
-1,882,382
-20% -$25.2M ﹤0.01% 1265
2023
Q2
$127M Buy
9,453,077
+1,910,359
+25% +$27.5M 0.01% 1065
2023
Q1
$125M Sell
7,542,718
-330,596
-4% -$5.45M 0.01% 1042
2022
Q4
$146M Buy
7,873,314
+317,891
+4% +$4.89M 0.01% 931
2022
Q3
$96.9M Buy
7,555,423
+2,117,944
+39% +$25.1M 0.01% 1116
2022
Q2
$38.1M Buy
5,437,479
+819,524
+18% +$6.01M ﹤0.01% 1828
2022
Q1
$38.3M Sell
4,617,955
-433,034
-9% -$3.06M ﹤0.01% 1925
2021
Q4
$34.2M Sell
5,050,989
-1,018,392
-17% -$6.7M ﹤0.01% 2084
2021
Q3
$32.2M Buy
6,069,381
+70,933
+1% +$388K ﹤0.01% 2135
2021
Q2
$34.5M Sell
5,998,448
-2,935,535
-33% -$15.1M ﹤0.01% 2123
2021
Q1
$41.2M Buy
8,933,983
+2,820,053
+46% +$11.2M ﹤0.01% 1887
2020
Q4
$20.4M Sell
6,113,930
-1,518,422
-20% -$5.1M ﹤0.01% 2227
2020
Q3
$22.7M Buy
7,632,352
+955,751
+14% +$3.74M ﹤0.01% 1967
2020
Q2
$30.8M Sell
6,676,601
-764,221
-10% -$3.43M ﹤0.01% 1764
2020
Q1
$28.6M Buy
7,440,822
+22,527
+0.3% +$92.5K ﹤0.01% 1602
2019
Q4
$27.8M Buy
7,418,295
+3,791,669
+105% +$17.7M ﹤0.01% 1905
2019
Q3
$19.3M Buy
3,626,626
+1,805,435
+99% +$9.62M ﹤0.01% 2091
2019
Q2
$6.99M Buy
1,821,191
+194,096
+12% +$838K ﹤0.01% 2653
2019
Q1
$8.3M Buy
1,627,095
+71,118
+5% +$209K ﹤0.01% 2551
2018
Q4
$2.99M Buy
1,555,977
+28,527
+2% +$81.7K ﹤0.01% 2953
2018
Q3
$5.77M Buy
1,527,450
+88,522
+6% +$277K ﹤0.01% 2792
2018
Q2
$4.49M Buy
1,438,928
+235,288
+20% +$714K ﹤0.01% 2916
2018
Q1
$2.88M Buy
1,203,640
+65,842
+6% +$219K ﹤0.01% 3031
2017
Q4
$4.45M Buy
1,137,798
+193,503
+20% +$639K ﹤0.01% 2841
2017
Q3
$2.38M Buy
944,295
+6,100
+0.7% +$16.7K ﹤0.01% 3126
2017
Q2
$2.59M Buy
938,195
+892,895
+1,971% +$1.86M ﹤0.01% 3026
2017
Q1
$88K Hold
45,300
﹤0.01% 3547
2016
Q4
$47K Hold
45,300
﹤0.01% 3565
2016
Q3
$49K Hold
45,300
﹤0.01% 3486
2016
Q2
$33K Sell
45,300
-1,148,674
-96% -$925K ﹤0.01% 3622
2016
Q1
$1.4M Buy
1,193,974
+61,345
+5% +$95.2K ﹤0.01% 3122
2015
Q4
$2.78M Buy
1,132,629
+102,198
+10% +$293K ﹤0.01% 2861
2015
Q3
$3.1M Buy
1,030,431
+369,172
+56% +$1.59M ﹤0.01% 2785
2015
Q2
$2.73M Buy
661,259
+616,859
+1,389% +$2.46M ﹤0.01% 2939
2015
Q1
$193K Hold
44,400
﹤0.01% 3497
2014
Q4
$133K Sell
44,400
-5,000
-10% -$13.7K ﹤0.01% 3532
2014
Q3
$164K Buy
49,400
+2,200
+5% +$5.75K ﹤0.01% 3494
2014
Q2
$120K Hold
47,200
﹤0.01% 3454
2014
Q1
$107K Hold
47,200
﹤0.01% 3502
2013
Q4
$92K Buy
+47,200
New +$95.4K ﹤0.01% 3491

Other funds holding CPRX

State Street's CPRX Position: Q1 2026 in Review

State Street reduced its Catalyst Pharmaceutical (CPRX) stake by 0.65% in Q1 2026, selling an estimated $1.06M and leaving 6,863,060 shares worth $170M. The position accounts for 0.01% of the portfolio, ranked #1035.

State Street first reported a position in CPRX in Q4 2013 and has held it in 50 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • State Street held 6,863,060 shares of Catalyst Pharmaceutical worth $170M as of Q1 2026.
  • State Street sold 44,562 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.06M.
  • Catalyst Pharmaceutical made up 0.01% of State Street's portfolio in Q1 2026, its #1035 holding.
  • State Street first reported a position in Catalyst Pharmaceutical in Q4 2013 and has held it in 50 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.